Batten Disease
StemCells, Inc. Provides Batten's Clinical Trial Update
Published in Medical Letter on the CDC and FDA, February 3rd, 2008
StemCells, Inc. (NASDAQ:STEM) today provided an update on the Company's Phase I clinical trial of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells). The trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a potential treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL). NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative condition afflicting infants and children. Enrollment and transplantation of all six patients planned for the trial has been completed.
"We are deeply saddened to learn that one of the patients in our trial has passed away,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- AFP Imaging Corporation
AFP Imaging Comments on Foreign Investor Trading Activity - Cancer
Research from Food & Drug Administration in the area of cancer published - Drug Development
New drug development research from Pfizer Inc. outlined - Enzyme Research
King Pharmaceuticals Reports FDA Approval of Revised Labeling Regarding Purity of THROMBIN-JMI(R) - Ligand Pharmaceuticals Incorporated
Ligand Partner Pfizer Submits NDA for Fablyn(R) - Lupus
ZymoGenetics Announces Special Protocol Assessment for Atacicept in General SLE - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
